Michail_Petrov-96
China’s Gan & Lee Pharmaceuticals has received FDA clearance to run a head-to-head Phase 2 study of its drug candidate GZR18 Injection against Eli Lilly’s (NYSE:LLY) weight-loss drug tirzepatide, also known as Zepbound and Mounjaro.
Gan & Lee said the study will
